H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.

3 years ago

Targets one of Healthcare’s Largest Multi-Billion Dollar Markets: Cardiac ElectrophysiologyTAMPA, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB:…

Healthcare Triangle Announces the Appointment of Sanjay Dalwani as Chief Revenue Officer

3 years ago

PLEASANTON, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (Nasdaq: HCTI) (“HCTI” or the "Company") a leading provider…

ORYZON Announces New Senior VP of Clinical Development and Global Medical Affairs, Continuing its Expansion of US Corporate Activities

3 years ago

Dr. Ana Limón is a specialist in Oncology with extensive industry experienceTo coordinate global clinical strategy in oncology from Boston,…

Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology

3 years ago

miCAR Platform Enables Simultaneous Silencing of Multiple Gene TargetsAllogene to Deploy miCAR and other Technologies to Create the Next Generation…

Fluidigm Announces Preliminary Revenue Exceeding Guidance for the Fourth Quarter and Full Year 2021

3 years ago

Fourth quarter preliminary revenue of $38.0 to $38.3 million Full year 2021 preliminary revenue of $130.3 to $130.6 million Base…

electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store

3 years ago

ROCKAWAY, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the…

Harpoon Therapeutics Provides Pipeline Development Milestones for 2022

3 years ago

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing…

Medolife Rx Presents Its Venom-To-Drug Development Projects at an International Conference Held in the Dominican Republic

3 years ago

BURBANK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company…

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones

3 years ago

Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of…

NRx Announces Planned Study Investigating BriLife™ Booster Vaccine Against Omicron Variant

3 years ago

Trial targeted to begin in the first quarter of 2022NRx is coordinating study with the US Health and Human Services…